Recently, there have been several consolidations in the economy, the biotech industry being one. With the creation of fewer "Biotech giants worldwide", will this lead to stronger monopoly power, thus potentially contributing to rising healthcare costs (prescription drugs), or is it a necessity of the industry to optimize R&D resources to more rapidly bring new, critical medicines to market?